Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $52.00.

Several research firms recently commented on KNSA. The Goldman Sachs Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Wedbush reaffirmed an “outperform” rating and issued a $48.00 price target (up previously from $44.00) on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, October 28th. TD Cowen began coverage on shares of Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They set a “buy” rating and a $60.00 price objective for the company. Wells Fargo & Company lifted their price objective on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Finally, Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CFO Mark Ragosa sold 19,900 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $40.94, for a total value of $814,706.00. Following the transaction, the chief financial officer directly owned 31,086 shares in the company, valued at approximately $1,272,660.84. This represents a 39.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sanj K. Patel sold 97,390 shares of the firm’s stock in a transaction dated Wednesday, October 22nd. The stock was sold at an average price of $38.83, for a total transaction of $3,781,653.70. Following the sale, the chief executive officer directly owned 111,794 shares in the company, valued at $4,340,961.02. This represents a 46.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 622,513 shares of company stock valued at $23,607,641. 53.48% of the stock is owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of hedge funds have recently bought and sold shares of the company. USA Financial Formulas purchased a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $32,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares during the last quarter. Quarry LP purchased a new stake in shares of Kiniksa Pharmaceuticals International in the third quarter valued at $44,000. Osaic Holdings Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at $31,000. Finally, Farther Finance Advisors LLC increased its stake in Kiniksa Pharmaceuticals International by 582.4% in the third quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock valued at $53,000 after purchasing an additional 1,159 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ KNSA opened at $42.49 on Friday. The business has a 50 day moving average price of $39.09 and a 200 day moving average price of $33.41. The company has a market capitalization of $3.22 billion, a P/E ratio of 94.42 and a beta of 0.16. Kiniksa Pharmaceuticals International has a 1-year low of $17.82 and a 1-year high of $42.98.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. During the same period last year, the company posted ($0.18) EPS. The firm’s revenue for the quarter was up 61.2% on a year-over-year basis. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, research analysts expect that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.